Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT-01
- Development stage
- Preclinical
- Lead developer
- Vivace Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VT-01 is an orally available small-molecule inhibitor of TEA domain (TEAD) transcription factors and Yes1 associated transcriptional regulator (YAP1), components of the Hippo signaling pathway that regulate cell proliferation and survival. By inhibiting TEAD–YAP1–mediated transcription, VT-01 is designed to suppress oncogenic gene expression programs in tumors with dysregulated Hippo pathway activity. Initially developed by Vivace Therapeutics for oncology indications, VT-01 is in preclinical development with lead programs focused on glioblastoma and meningioma.[1]
02
Targets
YAP1 (YES-associated protein–transcriptional enhancer factor domain complex)TEAD (TEAD family)
Beyond the preview
Go deeper on VT-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT-01.